MedTrace Logo

Effect of Pioglitazone Versus Metformin on Bone Health in Postmenopausal Women With Type 2 Diabetes

NCT01935804 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 440

Last updated 2014-06-17

No results posted yet for this study

Summary

The study tests whether pioglitazone (PIO)as compared to metformin (MET)affects bone health including bone mineral density, bone turnover markers, and osteocyte biomarker in patients with type 2 diabetes (T2DM).

Conditions

Interventions

DRUG

Pioglitazone

30 mg/daily for 12 months

DRUG

Metformin

850 mg/daily for 12 months

Sponsors & Collaborators

  • King Abdulaziz University

    lead OTHER

Principal Investigators

  • Mohammed-Salleh M Ardawi, PhD, FRCPath · Center of Excellence for Osteoporosis Research and Faculty of Medicine, King Abdulaziz University

  • Abdulrahim A Rouzi, FRCPC · Center of Excellence for Osteoporosis Research, and Faculty of Medicine, King Abdulaziz University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2014-01-31
Completion
2014-01-31

Countries

  • Saudi Arabia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01935804 on ClinicalTrials.gov